Ireland-headquartered Jazz Pharmaceuticals PLC will pay $30.25 per share in cash, or approximately $1.5bn, to acquire small US pharma Celator Pharmaceuticals Inc. for its lead cancer therapy, Vyxeos.
As the rest of Celator's pipeline appears void of other smash hits, Vyeos could be a number one for Jazz....





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
